Jun 20, 2019

This included a $100m Series D equity financing and a $70m credit facility. The Series D equity financing included new investors 8VC, Opaleye Management, Pura Vida Investments, and existing investors OrbiMed, Deerfield Management Company, Advent Venture Partners, Xeraya Capital and GE Ventures. The credit facility was provided by OrbiMed Credit and Royalties Fund and Deerfield Management. The company intends to use the funds to accelerate commercialization and facilitate global business development activities. Proceeds will allow Acutus to increase market availability of its FDA and CE marked AcQMap™ products as well as a suite of FDA-cleared, EP-designed vascular access products – AcQCross QX, AcQGuide Flex™ and AcQGuide Mini™. Founded in 2011 by Vince Burgess, CEO, Acutus provides next-generation electrophysiology technology solutions that can enable personalized and adaptive approaches to therapy. Its AcQMap is cardiac imaging and mapping system that incorporates precision ultrasound atrial anatomy reconstruction and reproducible, high-definition non-contact charge density mapping. The system also provides workhorse contact mapping capabilities, available in Europe. AcQMap’s increased clarity of arrhythmia pattern mapping aids in the development of patient specific ablation strategies. FinSMEs 20/06/2019